Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.

ABSTRACT:

Background

Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood.

Methods

Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regimens in a single institution from September 2017 to May 2018 were enrolled in this study. PD-L1 expression in tumor cells (TC) and mismatch repair (MMR) were analyzed by immunohistochemistry. Epstein-Barr virus (EBV) was detected by in situ hybridization. Cancer genome alterations were evaluated by a next-generation sequencing-based panel. High tumor mutation burden (TMB) was defined as more than 10 mutations/megabase.

Results

A total of 80 pts were analyzed in this study. Tumor response was evaluated in 72 pts with measurable lesion

SUBMITTER: Mishima S 

PROVIDER: S-EPMC6357506 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature